#China #Guangzhou #Simcere #Fermion #FZ002-037

Exciting Development in Pain Management

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a groundbreaking partnership aimed at developing FZ002-037, China’s first SSTR4 agonist specifically designed to address pain management. This innovative medication is currently in its clinical trial phases and promises to offer an effective solution for patients experiencing chronic pain without the risk of addiction.

FZ002-037 is a small molecule, highly selective oral agonist for the SSTR4 receptor. Preclinical studies have shown that it primarily provides peripheral analgesia, making it a highly promising option for long-term pain treatment. This drug has completed phase I clinical trials in China successfully. Subsequently, phase II trials will soon commence for patients suffering from diabetic peripheral neuropathy, with hopes of expanding its application to a variety of chronic and acute pain conditions.

Doctor Deco Deng, the founder of Fermion, expressed enthusiasm about this collaboration. He stated, “We are thrilled to partner with Simcere, a leading pharmaceutical company. As the first highly selective SSTR4 agonist developed nationally and the second worldwide to enter clinical trials, FZ002-037 holds significant promise. By leveraging Simcere’s robust development and commercialization capabilities, we are confident in accelerating its progress to provide better treatment options for patients enduring pain.”

Simcere's director of investments, Zhou Gaobo, emphasized the substantial impact pain has on patients' quality of life. He noted, “Addressing these pressing clinical concerns has always been a vital mission for Simcere. We anticipate collaborating with innovative partners like Fermion to deliver more effective and safer pain therapies to patients as soon as possible.”

Under the terms of their agreement, Simcere will have the exclusive rights to develop and market FZ002-037 across Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. Fermion will receive an upfront payment, milestone payments, and a tiered royalty based on future sales, ensuring mutual benefits for both companies.

About Fermion Technology

Founded in 2019, Fermion Technology is a clinical-stage biotechnology company utilizing artificial intelligence to develop differentiated first-in-class and best-in-class therapeutics in areas such as central nervous system disorders and autoimmune diseases. Leveraging their proprietary AI Drug Studio platform, Fermion prioritizes high target selectivity and tissue-specific targeting to minimize side effects, ensuring precise distribution to target tissues while promoting safer, innovative drug development.

For further details, visit Fermion's website.

About Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited, listed on the Hong Kong Stock Exchange (2096.HK), focuses on research-driven innovation and operates a Key State Laboratory for Neurological and Oncology Drug Development. Committed to providing patients with future therapeutics today, Simcere targets oncology, central nervous system disorders, autoimmune conditions, and anti-infectives, while expanding into therapeutic areas with significant unmet clinical needs in the near future.

With industry-leading capabilities and a commitment to synergistic innovation, Simcere has fostered numerous strategic collaborations, positioning itself as a preferred partner for innovative biopharmaceutical companies, medical institutions, and research teams both domestically and globally.

For more information, visit Simcere's website.

Overview of FZ002-037

FZ002-037 represents a non-opioid analgesic ready for phase II trials, acting as an oral SSTR4 agonist. It is notable for being thefirst SSTR4 agonist to enter clinical trials in China and the second globally. The drug showcases exceptional selectivity, demonstrating efficacy across various chronic and acute pain models. Phase I studies have indicated a favorable safety profile, with no reported central nervous system or gastrointestinal adverse events and an attractive pharmacokinetic profile allowing for potential once-daily dosing. These aspects highlight its potential as an innovative therapeutic option to meet the unmet medical need for effective and non-addictive pain relief.

For additional inquiries, please contact [email protected]